Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_1215 |
| Primary information | |
|---|---|
| B3PDB ID | b3pdb_1215 |
| Peptide Name | P19 |
| PEPTIDE SEQUENCE (1-letter) | VQILYK |
| PEPTIDE SEQUENCE (3-letter) | NA |
| N-terminal modification | NA |
| C-terminal modification | C-terminal amidation |
| Chemical modification | NA |
| Peptide Length | 6 |
| Conformation | Linear |
| Peptide Nature | NA |
| Source/Origin of peptide | Chemically synthesized |
| SMILES | NA |
| Cell Line | Human brain endothelial cells (EA.hy926) |
| In vitro CONCENTRATION | NA |
| In vitro METHOD | Field-emission transmission electron microscope |
| In vitro RESULT | A3 peptide treated with this peptide, showed higher folds of decrease in fluorescence intensities a |
| ANIMAL MODEL | NA |
| In vivo CONCENTRATION | NA |
| In vivo MODE OF DELIVERY | NA |
| In vivo METHOD | NA |
| In vivo RESULT | NA |
| ACTION | Trojan peptides are capable of translo- cating the BBB, without affecting its interity. |
| TRANSPORT TYPE | Translocation |
| SUBCELLULAR LOCALISATION | NA |
| COMBINATION | Comined with A3 pepide |
| PHYSICAL CONDITION | Tauopathies |
| RESPONSE | These peptides were capable of reducing the tau elicit toxicity by accelerating or impeding the self |
| RESULT | These peptide-based modulators (Trojans) were non-amyloidogenic, stable in serum and showed minimal |
| LABEL | NA |
| PMID | 32114026 |